Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.
about
Myocardial reperfusion injury: looking beyond primary PCIPI3Kγ in hypertension: a novel therapeutic target controlling vascular myogenic tone and target organ damageA role for a CXCR2/phosphatidylinositol 3-kinase gamma signaling axis in acute and chronic vascular permeability.Myocardial survival signaling in response to stem cell transplantation.Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allograftsPI3Kδ inhibition reduces TNF secretion and neuroinflammation in a mouse cerebral stroke model.Phosphatidylinositol-3-kinase gamma plays a central role in blood-brain barrier dysfunction in acute experimental stroke.Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse.Redox-sensitive oxidation and phosphorylation of PTEN contribute to enhanced activation of PI3K/Akt signaling in rostral ventrolateral medulla and neurogenic hypertension in spontaneously hypertensive ratsSemaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factorMyocardial ischemia-reperfusion injury: a neglected therapeutic target.Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosisAloperine protects mice against ischemia reperfusion (IR)-induced renal injury by regulating PI3K/AKT/mTOR signaling and AP-1 activity.Role of phosphoinositide 3-kinase signaling in autoimmunity.Pharmacologic therapeutics for cardiac reperfusion injury.Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.The magnitude and temporal dependence of apoptosis early after myocardial ischemia with or without reperfusion.H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors.Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?Novel inhibitors of the PI3K family.PI3K inhibitors in cardiovascular disease.Therapeutic applications of PI3K inhibitors in cardiovascular diseases.Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.Role of phosphoinositide 3-kinase in the pathogenesis of acute pancreatitis.PI3K inhibitors in inflammation, autoimmunity and cancer.Inhibition of p110δ PI3K prevents inflammatory response and restenosis after artery injury.Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice.Phosphoinositide 3-kinase gamma gene knockout impairs postischemic neovascularization and endothelial progenitor cell functions.Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities.A microwave assisted intramolecular-furan-Diels-Alder approach to 4-substituted indoles.Chronic treatment with LY294002, an inhibitor of phosphatidylinositol 3-kinase, attenuates ischemia/reperfusion-induced cardiac dysfunction in normotensive and hypertensive diabetic animals.PI3Kγ inhibition reduces blood pressure by a vasorelaxant Akt/L-type calcium channel mechanism
P2860
Q26991482-21272330-2A90-40B7-BC7A-A27BCBA11184Q27026365-7E6D2B3F-6477-4C8B-8EC8-039536CE893AQ28566820-43B0877A-8D69-45F9-AE01-1A72E0667EDDQ33635730-3615DC40-DB06-4367-8002-B6B71FA4CF1DQ34221228-EFE5BB46-0A63-44A4-ACC4-41D713F3C50DQ34409918-A2CA8CCF-92C9-4BF6-B13F-76B6AC13D07AQ35086740-B1C3AB58-5092-45C1-B933-F81F98554A66Q35129307-2FC6F99F-4229-4C4C-A7C1-68B7DC13922EQ36096234-78383ED6-DBFF-4F2B-999F-6F872D78A31AQ36415676-3FD4E968-6336-497B-8EBE-74657DE4EA0CQ36478465-F81FB17B-EEA7-4AF1-9E50-6F171F07D378Q36497176-13A1DB71-3294-443E-89A2-8DF51D6CF0A6Q36641630-75216CAD-045F-4B9B-B027-7D0919F2A717Q36758002-30D9441B-CBB8-4D20-99DB-D38BBD72C89FQ36922987-D688BD1E-AA83-468B-8811-9C7068F1921AQ36944008-E29254CF-0776-473D-981B-20518A4DD181Q37090971-6CCF818A-FE1D-43F4-9019-B44D3F22E1C0Q37139791-BBCB4D17-6ED8-44A9-801D-828A6505DBC0Q37346629-9004F33E-C96A-4B7F-AC96-C128D685F77AQ37461480-84FE0543-A287-4D66-A446-0743E4312F58Q37546115-AE698F65-E2A3-4C99-A4BA-BB59F13B036FQ37772192-2309A841-AA6D-447B-AB76-5876C8394FFCQ38089742-D1CF7018-43FD-4D3C-9274-398EAD5E9A26Q38134311-3066020F-A661-4D46-AD61-9CFC60347295Q38266869-ADF19DFA-9B33-4935-9615-B082B8220AFCQ38532898-DAF01261-8C09-4D22-9B60-73748C2EACE7Q38603120-DBC0931B-97B1-4541-AECF-D7A64F216EF5Q39441600-31CD581E-73B4-4BB0-A1C3-AE997D5CD094Q41838531-99640102-A676-4DE0-9B77-4F798DB63B71Q42178173-65951417-22C0-42B6-BF16-B07B0E307254Q42543241-A1B2166B-327A-4D54-BD93-FD966714A401Q54473465-9E12C538-DF90-4923-8EA2-1A1803FAFE0BQ57005928-4F4DC3A2-ABA7-4D24-A286-743DAB86833E
P2860
Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phosphoinositide 3-kinase gamm ...... l ischemia/reperfusion injury.
@ast
Phosphoinositide 3-kinase gamm ...... l ischemia/reperfusion injury.
@en
type
label
Phosphoinositide 3-kinase gamm ...... l ischemia/reperfusion injury.
@ast
Phosphoinositide 3-kinase gamm ...... l ischemia/reperfusion injury.
@en
prefLabel
Phosphoinositide 3-kinase gamm ...... l ischemia/reperfusion injury.
@ast
Phosphoinositide 3-kinase gamm ...... l ischemia/reperfusion injury.
@en
P2093
P2860
P356
P1476
Phosphoinositide 3-kinase gamm ...... l ischemia/reperfusion injury.
@en
P2093
Anthony Demaria
David Cheresh
Elena Dneprovskaia
Glenn Noronha
John Doukas
Richard Fine
Richard Soll
Wolfgang Wrasidlo
P2860
P304
19866-19871
P356
10.1073/PNAS.0606956103
P407
P577
2006-12-15T00:00:00Z